Literature DB >> 7522872

Similarity of the American Urological Association Symptom Index among men with benign prostate hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction.

M B Chancellor1, D A Rivas, F X Keeley, M A Lotfi, L G Gomella.   

Abstract

OBJECTIVE: To compare the specificity of the American Urological Association (AUA) Symptom Index for benign prostatic hyperplasia (BPH) versus other urodynamically verified micturitional dysfunction in men. PATIENTS AND METHODS: Fifty-seven consecutive men who had been referred for video-urodynamic evaluation of voiding symptoms were evaluated. The patients were divided into three groups: (i) BPH group (n = 24); (ii) non-BPH obstructed group (n = 20; nine bladder neck obstruction, 11 bulbous urethral stricture); and (iii) detrusor hyper-reflexia group: detrusor hyper-reflexia without outlet obstruction (n = 13).
RESULTS: The mean AUA symptom score for the BPH group was 18.9 (range 7-28). The mean score for the 20 non-BPH obstructed group was 17.6 (range 4-28) and the mean score for the 13 men with detrusor hyper-reflexia was 20.5 (range 12-27). There was no statistical difference in the AUA symptom score among the three groups.
CONCLUSION: The AUA Symptom Index does not specifically identify BPH or bladder outlet obstruction. The index cannot differentiate the site of obstruction as noted by the similar scores among men with BPH from those with bladder neck obstruction and urethral strictures. Moreover, The AUA Symptom Index scores are similar between men with voiding symptoms secondary to bladder dysfunction and bladder outlet obstruction.

Entities:  

Mesh:

Year:  1994        PMID: 7522872     DOI: 10.1111/j.1464-410x.1994.tb16586.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  14 in total

1.  Bladder-outlet obstruction--assessment of symptoms.

Authors:  J M Reynard; P Abrams
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 2.  Benign prostatic hyperplasia.

Authors:  R J Simpson
Journal:  Br J Gen Pract       Date:  1997-04       Impact factor: 5.386

3.  The American Urological Association Symptom Index: early postoperative evaluation of irritative and obstructive symptoms due to benign prostatic hyperplasia.

Authors:  O Ichiyanagi; M Ishigooka; T Hashimoto; S Hayani; Y Suzuki; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score.

Authors:  I Araki; S Kuno
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

5.  Role of symptom scoring and uroflowmetry in patients with diabetic cystopathy.

Authors:  M Ishigooka; Y Suzuki; S Hayami; O Ichiyanagi; T Hashimoto; T Nakada
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

Review 6.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Stimulation of the tibial nerve-a randomised trial for urinary problems associated with Parkinson's-the STARTUP trial.

Authors:  Doreen McClurg; Andrew Elders; Suzanne Hagen; Helen Mason; Jo Booth; Anne-Louise Cunnington; Richard Walker; Katherine Deane; Danielle Harari; Jalesh Panicker; Susan Stratton; Jaclyn McArthur; Ceri Sellers; Marissa Collins
Journal:  Age Ageing       Date:  2022-06-01       Impact factor: 12.782

Review 8.  Pelvic ultrasound evaluation for benign prostatic hyperplasia: prediction of obstruction.

Authors:  Daniel B Rukstalis
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

9.  Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion.

Authors:  Seung Wook Lee; Jeong Man Cho; Jung Yoon Kang; Tag Keun Yoo
Journal:  Korean J Urol       Date:  2010-10-21

10.  [Pharmacological treatment of benign prostatic hyperplasia].

Authors:  M Oelke; M A Kuczyk; T R W Herrmann
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.